A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)
Journal of Biological Chemistry
Enzalutamide, a nonsteroidal secondgeneration antiandrogen, has been recently approved for the management of castrationresistant prostate cancer (CRPC). Although patients can benefit from enzalutamide at the beginning of this therapy, acquired enzalutamide resistance usually occurs within a short period. This motivated us to investigate the mechanism involved and possible approaches for overcoming enzalutamide resistance in CRPC. In the present study, we found that HMG-CoA reductase (HMGCR), adoi:10.1074/jbc.ra118.004442 pmid:30089652 fatcat:am3t4zvadfcm7c4z5buwpkerby